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Abstract
Variance between studies in a meta-analysis will exist. This heterogeneity may be of clinical, methodological or statistical origin. The last of
these is quantiﬁed by the I2-statistic. We investigated, using simulated studies, the accuracy of I2 in the assessment of heterogeneity and the
effects of heterogeneity on the predictive value of meta-analyses. The relevance of quantifying I2 was determined according to the likely
presence of heterogeneity between studies (low, high, or unknown) and the calculated I2 (low or high). The ﬁndings were illustrated by
published meta-analyses of selective digestive decontamination and weaning protocols. As expected, I2 increases and the likelihood of
drawing correct inferences from a meta-analysis decreases with increasing heterogeneity. With low levels of heterogeneity, I2 does not
appear to be predictive of the accuracy of the meta-analysis result. With high levels of heterogeneity, even meta-analyses with low I2-values
have low predictive values. Most commonly, the level of heterogeneity in a meta-analysis will be unknown. In these scenarios, I2
determination may help to identify estimates with low predictive values (high I2). In this situation, the results of a meta-analysis will be
unreliable. With low I2-values and unknown levels of heterogeneity, predictive values of pooled estimates may range extensively, and
ﬁndings should be interpreted with caution. In conclusion, quantifying statistical heterogeneity through I2-statistics is only helpful when the
amount of clinical heterogeneity is unknown and I2 is high. Objective methods to quantify the levels of clinical and methodological
heterogeneity are urgently needed to allow reliable determination of the accuracy of meta-analyses.
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The meta-analysis has become one of the most widely used
methods to quantify the effects of medical interventions. In
fact, in grading the evidence base of medical practice, a
properly designed meta-analysis is considered to be equally as
relevant as a large randomized controlled trial, as one of both
is needed to reach so-called level I evidence [1]. As such,
meta-analyses generally constitute the starting point, and
frequently the most prominent component, of guidelines for
clinical management. Furthermore, clinicians are increasingly
using meta-analyses to remain up-to-date, and funding agencies
frequently require such an analysis to justify further research.
The number of published systematic reviews and meta-analy-
ses has increased substantially in the last decade, including in
the ﬁeld of infectious disease medicine.
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Ideally, a meta-analysis combines the results of several
studies that are highly comparable in design, intervention, and
patient population. The individual studies have similar trends in
outcome, but lack sufﬁcient statistical power for a deﬁnite
conclusion to be drawn. However, in real life, meta-analyses
frequently contain multiple, relatively small studies that differ in
many respects (such as in dosing schedules, duration of
follow-up, types of participants, and modes of treatment and
diagnosis).
Naturally, studies brought together in a meta-analysis will
differ, and this is also called ‘heterogeneity’. Generally, a
distinction is made between clinical heterogeneity (differences
in, for example, patient populations and treatment protocol),
methodological heterogeneity (differences in study design and
risk of bias), and statistical heterogeneity (larger differences in
the outcome of the individual studies than could expected to
result from chance alone, which may result from clinical or
methodological heterogeneity).
Tests for statistical heterogeneity, such as Cochran’s Q-sta-
tistic and the I2-statistic, are commonly used in meta-analyses to
determine whether there are genuine differences underlying the
results of the studies, or whether the variation in ﬁndings is
compatible with chance alone. The most commonly used test is
the I2-statistic, which expresses the level of heterogeneity as a
percentage, and can be compared across meta-analyses with
different sizes and outcomes [2].
The appraisal of the similarity of studies with regard to
clinical and methodological heterogeneity and the ultimate
decision of whether to include (or exclude) a certain study in a
meta-analysis are the responsibility of the meta-analysts. As
there are no criteria with which to quantify clinical and
methodological heterogeneity, this appraisal is subjective.
Although the quantiﬁcation of statistical heterogeneity seems
to be more objective (e.g. by calculating the I2-value), the
predictive value of this test for the accuracy of the estimate
derived from the meta-analysis is unknown. Furthermore,
there is no uniform approach to dealing with heterogeneity.
Multiple strategies have been proposed [3], and there are
many examples of meta-analyses being performed in the
presence of substantial heterogeneity. In this study, we
investigated, by using a simulation model, the accuracy of the
I2-statistic in the assessment and quantiﬁcation of heteroge-
neity, and how heterogeneity across studies relates to the
predictive value of meta-analyses. First, we brieﬂy explain the
concepts of heterogeneity. Subsequently, the objectives and
the results of our simulation model are presented. Finally, we
illustrate and clarify our ﬁndings by presenting common
scenarios including several examples of meta-analyses evaluat-
ing different interventions published in the ﬁeld of infectious
diseases and critical-care medicine.
Heterogeneity
Heterogeneity across studies includes all differences between
individual studies related to, among other factors, study design,
populations included, treatment strategies, and outcomes. For
simplicity, we distinguish two types of heterogeneity: ‘owing to
chance’ and ‘systematic’.
Even when the strictest selection criteria for study inclusion
are used, it is impossible to avoid some kind of heterogeneity
between studies performed under different conditions. In fact,
even in the hypothetical situation of a single study being
executed multiple times under exactly the same conditions,
the outcome will, owing to chance events, not be exactly the
same for each evaluation. In addition to this unavoidable
heterogeneity owing to chance, there is a possibility of
heterogeneity owing to systematic differences between the
studies, such as differences in study design, patient popula-
tions, diagnostic methods, application of interventions, or
deﬁnitions of outcome. Some level of heterogeneity can be
avoided by using strict criteria of study selection, based on
design (i.e. only double-blind randomized trials instead of any
randomized trial), populations (only mechanically ventilated
trauma patients instead of all types of mechanically ventilated
patients), and outcomes (i.e. only day 28 mortality instead of
mortality measured at different time-points). Therefore,
although heterogeneity can be avoided to some extent, it
can never be prevented completely. However, the predictive
value of meta-analyses is unknown in the case of systematic
heterogeneity.
Several methods have been proposed for quantiﬁcation of
heterogeneity in meta-analyses [3]. Such a test examines the
null hypothesis that all studies have evaluated the same effect.
Cochran’s Q reﬂects the sum of the squared deviations of the
study’s estimate from the overall pooled estimate, weighing
each study’s contribution in the same way. However, this test
is poor in detecting true heterogeneity, especially when small
numbers of studies are being dealt with.
I2 reﬂects the percentage of total variation across studies
that is attributable to heterogeneity rather than chance, and is
calculated from Cochran’s Q as 100% 9 (Q  degrees of
freedom)/Q. Negative I2-values are considered as 0%, which
indicates no observed heterogeneity. Heterogeneity can be
quantiﬁed as low, moderate, and high, with upper limits of 25%,
50% and 75% for I2, respectively. Calculation of I2 has now
become the standard way of reporting heterogeneity in all
Cochrane reviews [2,3]. Interestingly, I2 is almost always
reported as a single value without a 95% CI, although these
areas can be wide, demonstrating the inherent uncertainty of
this value [4]. It is neither possible to quantify the exact level of
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heterogeneity across studies nor to distinguish the contribu-
tion of chance and systematic heterogeneity.
Adequately dealing with heterogeneity is often difﬁcult,
although some guidelines are provided [3]. Important ques-
tions are whether heterogeneity is too large for a meaningful
meta-analysis, and what particular model should be used for
calculation of the pooled estimate. For the latter, two models
are used [3]: (i) the ﬁxed-effects model, which assumes that all
of the included studies are estimating the true effect, and that
variation in ﬁndings among the studies is therefore attributable
to chance only; and (ii) a random-effects model, which assumes
that the effects estimated in the different studies follow a
distribution, resulting in a wider CI of the pooled estimate.
Methods
In our simulation model meta-analyses were performed of
simulated randomized controlled trials evaluating a certain
intervention that had varying amounts of heterogeneity, with
the following assumptions. We assume an intervention with
25% efﬁcacy (e.g. mortality reduction), and that the outcome
occurs in 15% of the population when the intervention is
performed (and thus in 20% without intervention). The
amount of systematic heterogeneity is expressed by r, which
is 0 in the absence of systematic heterogeneity. Monte Carlo
simulations are used to perform multiple meta-analyses, each
including ten studies with two groups of 100 patients. For each
simulated study, the expected mortalities are 0.20 and 0.15 in
the control and intervention arms, respectively. In the
intervention group, however, we deliberately modify the
amount of heterogeneity (see methods in Supporting Infor-
mation). Meta-analysis results were compared with the true
average relative risk of simulated studies and with a (simulated)
reference study with an inﬁnite number of patients, which
therefore always yields the average incidence of 0.15. We
determined: (i) whether the 95% CI of the meta-analysis
contains the true average relative risk of 0.15/0.20 = 0.75; and
(ii) whether the outcome of the 11th study falls within the
95% CI of the preceding meta-analysis. Note that (i) and (ii)
need not to coincide. If (i) is true, the meta-analysis has
predicted a correct estimate of the intervention, which should
happen in 95% of the meta-analyses if the appropriate method
is used. However, in practice, a meta-analysis is often
considered to have provided a correct estimate if this
coincides with the results of a single large trial (ii). The
meta-analyses from simulated studies are repeated 107 times
per value of heterogeneity to determine associations between
the likelihood of predicting the correct estimate of effect, I2,
and the amount of heterogeneity.
Results
With a random-effects meta-analysis, the 95% CI of the effect
estimate contains the true relative risk (0.75) in at least 81% of
the simulations, and with low systematic heterogeneity
between intervention arms (r < 0.05), the 95% CI contains
the true relative risk in at least 93% of all experiments (Fig. 1a).
In fact, the CI obtained from a random-effects meta-analysis
has the desired properties as long as the differences between
studies are more or less normally distributed (see methods in
Supporting Information).
However, the 95% CI of a meta-analysis does not accurately
predict the outcome of a single large study. In a series of ﬁgures
(Fig. 1 and Figs S2–S4), we have depicted the associations
(a)
(b)
FIG. 1. Results of the Monte Carlo simulation study. The associations
between the I2-statistic and the probability (%) that the true average
relative risk (a) and the result of the reference study (b) are contained
in the 95% CI of the meta-analysis, according to different levels of
heterogeneity. The dotted line represents the average I2-statistic. The
coloured lines represent the probabilities with a ﬁxed-effects model
(red) and a random-effects model (blue). MH, calculations based on a
ﬁxed-effects model with the Mantel–Haenszel method; RMH, calcula-
tions based on a random-effects model with the Mantel–Haenszel
method.
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between the accuracy of estimates derived from meta-analyses
and the chance that the result of the 11th study falls within the
95% CI of the meta-analysis estimate, as well as the chance that
it contains the true relative risk, with increasing amounts of
heterogeneity. As expected, I2 increases and the likelihood of
drawing correct inferences from a meta-analysis decreases
with increasing heterogeneity (Fig. 1). With a random-effects
model, the chances of correct estimates are higher than with a
ﬁxed-effects model, especially when heterogeneity increases
(Fig. 1).
Surprisingly, however, in the case of low levels of hetero-
geneity (r close to 0), I2 appears to be not predictive of the
accuracy of the meta-analysis result. With low amounts of
heterogeneity (r close to 0%), even ﬁxed-effects meta-analyses
with I2 > 75% yield highly accurate results (Fig. S2). With high
levels of heterogeneity, even meta-analyses with low I2-values
have low predictive values (Fig. S2). With a random-effects
model, the width of the 95% CIs increases with increasing I2,
which increases the likelihood of the 11th study result falling
within the CI limits (Fig. S3). However, the likelihood of
obtaining low I2-values also depends on the amount of
heterogeneity (Fig. S4). In the absence of any heterogeneity
(a pure theoretical option), the chance of ﬁnding a high I2
(>50%) is very low, but this rapidly increases with increasing
levels of heterogeneity. However, even with high heterogene-
ity (large r), low I2-values can be derived. All simulations were
repeated with an inverse variance method (instead of the
Mantel–Haenszel method), leading to identical results (data
not shown).
How do these results relate to the daily practice of
performing meta-analyses? We propose six different scenarios,
depending on the amount of expected methodological and
clinical heterogeneity (low, high, and unknown) and the
I2-values (high and low) that may occur when a meta-analysis
is performed (Fig. 2).
Scenarios 1 and 2
These scenarios relate to situations in which considerable
heterogeneity is probably attributable to differences between
studies (e.g. differences in study design, patient populations,
diagnostic methods, application of interventions, or deﬁnitions
of outcome). Calculated I2-values can be low (scenario 1) or
high (scenario 2), but even low I2-values (scenario 1) can be
associated with a low predictive values of meta-analysis results
(Fig. S2). A high I2 (scenario 2) is intuitively correct, consid-
ering the obvious amount of clinical and methodological
heterogeneity, and only conﬁrms what was already expected.
The high I2, however, will have broad CIs if a random-effects
method is used, which will contain the true average relative
risk in approximately 95% of the simulations. However, the
95% CI of the meta-analysis will not contain the result of the
large 11th study in at least 95% of the simulations. Thus,
calculation of I2 in both scenarios is of limited value: in
scenario 1, a low I2 can be obtained, which is associated with
low predictive values of meta-analysis results; in scenario 2, it
only conﬁrms what was already known (i.e. high levels of
heterogeneity with low accuracy of the meta-analysis).
Scenarios 3 and 4
These scenarios relate to situations where, based on the
similarity of the included studies, a low amount of heteroge-
neity is expected. The chance of obtaining a high I2 (scenario 4)
is low (Fig. S4), but the accuracy of the meta-analysis result will
still be as high as with low I2-values (scenario 3) (Fig. S2).
Therefore, with extremely low levels of heterogeneity, I2-val-
ues are not informative regarding the accuracy of meta-analy-
ses.
Scenarios 5 and 6
These scenarios relate to (probably frequent) situations in
which differences between studies exist, but where the impact
of these differences on the pooled estimates are unknown. In
such situations, a reliable statistical method to quantify the
amount of heterogeneity is especially needed. In our simulation
studies, high I2-values (>75%) (scenario 6) are predictive for
the presence of heterogeneity (Fig. S4) and low predictive
values of the estimates derived (Fig. S2). However, low
I2-values (scenario 5) correspond to a wide range of system-
atic heterogeneity levels, and thus to a high level of uncertainty
about the predictive value of meta-analysis results. Even when
I2 = 0, systematic heterogeneity can exist, which will reduce
the reliability of the pooled estimate. In real life, levels of
heterogeneity of most meta-analyses will be unknown. In these
scenarios, I2 determination may help to identify estimates with
low predictive values (high I2). In this situation, the results of a

































FIG. 2. Clinical scenarios.
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unknown levels of clinical and methodological heterogeneity,
predictive values of pooled estimates may range extensively,
and ﬁndings should be interpreted with caution.
We illustrate only the ﬁrst two scenarios, as scenarios 3
and 4 are scarce and scenarios 5 and 6 unknown, with two
clinical examples of meta-analyses published in the ﬁeld of
infectious diseases and critical-care medicine.
Clinical example I
The effectiveness of selective decontamination of the digestive
tract (SDD) has been evaluated in several meta-analyses
(Table 1) [5–11]. These meta-analyses included different
studies, partly because not all studies were available at the
time of preparation, or because different selection criteria
were applied. There were also differences in the aggregate
data used per study; some meta-analyses preferably used
intention-to-treat data, whereas others preferably used the
data of patients with a length of stay of at least 48 h. Also,
some used the hospital mortality data when available, whereas
others only used intensive-care unit (ICU) mortality. Despite
these differences, the pooled estimate of efﬁcacy of SDD in
reducing mortality remained more or less stable with ORs
around 0.80, being statistically signiﬁcant in the most recent
analyses. Silvestri et al. [10] summarized the characteristics of
the 30 studies included in their meta-analysis. Mortality in
control patients ranged from 3% to 58% (average of 25% with
a standard deviation of 15%), the methodological study quality
ranged (on a scale of 16) from 6 to 14 (average of 9  5), 11
different patient populations were studied, 11 different
intravenous medications were tested (including no prophy-
laxis), 11 of 30 studies used intravenous prophylaxis in control
patients, two studies evaluated oropharyngeal decontamina-
tion only, and three evaluated intestinal decontamination only.
Because of these differences, we ﬁrmly believe that there is
considerable heterogeneity between the studies. However,
even with all of these differences, the calculated I2 in this
meta-analysis is 0%, and similarly as low as for the other
meta-analyses. On the basis of study characteristics, hetero-
geneity was expected to be high, but this was not reﬂected by
the obtained I2-values, resembling scenario 1. After publica-
tion of these meta-analyses, the effects of SDD on patient
outcome were reported from a multicentre trial including
more patients (n = 5939) than in all of the studies included in
the most recent meta-analysis [12]. In this multicentre study,
SDD was, as compared with standard care, associated with a
13% reduction in day 28 mortality, which corresponded to an
adjusted OR of 0.83. This result was remarkably similar to the
results obtained in previous meta-analyses. Thus, despite
obvious methodological and clinical differences between
individual studies, the meta-analyses seemed to have accu-
rately predicted the effects of SDD.
Clinical example II
In another meta-analysis, the effects of weaning protocols on
the duration of mechanical ventilation in critically ill adult
patients was determined [13]. Eleven studies, both randomized
and quasi-randomized controlled trials, were selected, evalu-
ating 1971 patients admitted to seven different types of ICU.
Only two studies used the same weaning protocol, and the
‘usual care’ in the control group comprised a wide variety of
practices. The authors used ﬁxed-effects models for
meta-analysis, and a random-effects model in the case of
statistical heterogeneity (deﬁned as I2 > 50% and/or chi-square
statistic p <0.05). The primary outcome was the duration of
mechanical ventilation with and without the weaning protocol,
which was estimated (with random-effects model) as mean
log 0.29 (95% CI 0.5 to 0.09). However, a substantial
amount of heterogeneity was quantiﬁed with I2 (I2 = 76%).
Subgroup analyses to assess the impact of type of ICU were
small (two to four studies), and did not reduce heterogeneity
as indicated with the statistical test. Several secondary
outcomes were tested; no heterogeneity was indicated (I2
was estimated as low) in the analyses concerning hospital
mortality (pooled estimate of 1.10, 95% CI 0.86–1.41, I2 = 0%,
p 0.46) and length of stay in the ICU (pooled estimate of
0.11, 95% CI 0.21 to 0.02, I2 = 0%, p 0.45), and marked
heterogeneity was indicated in the analyses of ICU mortality
(pooled estimate of 0.98, 95% CI 0.48–2.02, I2 = 57, p 0.07)
and duration of weaning (pooled estimate of 1.52,
95% CI 2.66 to 0.37, I2 = 97%, p <0.001). The authors
concluded the following: ‘compared with usual care, use of
weaning protocols can reduce the duration of mechanical
ventilation by 25%, weaning duration by 78% and length of stay
in the ICU by 10%. As there was signiﬁcant heterogeneity in
included trials and most were conducted in the US, these
ﬁndings might not be generalisable.’ Indeed, heterogeneity was




studies OR (95% CI) I2 (%)
Vandenbroucke-Grauls 1991 7 0.70 (0.45–1.09) 0
SDD CTG 1993 15 0.80 (0.67–0.97) 0
Heyland 1994 24 0.83 (0.71–0.98) 0
Kollef 1994 16 0.88 (0.72–1.08) 0
Hurley 1995 26 0.86 (0.74–0.99) 5
D’Amico 1998 17 0.80 (0.69–0.93) 10
Silvestri 2007 30 0.80 (0.69–0.94) 0
Pooled ORs as provided in the meta-analysis or calculated from the information in
the manuscript of the meta-analyses. I2, when unavailable, was calculated by use of
the chi-squared statistic and degrees of freedom. The meta-analysis of SDD CTG
was updated; here, only the results of the ﬁrst publication are provided.
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expected to be high in this meta-analyses (owing to differences
in intervention, control groups, and patient population), and
this was conﬁrmed by a high I2 in many analyses, thereby
resembling scenario 2. The estimates obtained should there-
fore be interpreted with extreme caution.
Discussion
In this study, we have demonstrated the crucial importance of
study selection (or, in other words, of minimizing clinical and
methodological heterogeneity) for the accuracy of pooled
estimates derived from meta-analyses. Quantifying statistical
heterogeneity through I2-statistics can be helpful in some
scenarios (when the amount of heterogeneity is unknown and
I2 is high), but is of no help in other scenarios (at the extremes
of heterogeneity levels and when the amount of heterogeneity
is unknown and I2 is low). Our ﬁndings underscore the need
for a critical appraisal of meta-analyses before their results are
accepted, and underscore the huge responsibility of meta-ana-
lysts (and peer reviewers and editors) in adequately perform-
ing, interpreting and reporting of meta-analyses.
The reliability of I2-statistics in quantifying levels of heter-
ogeneity has been questioned before, albeit without determi-
nation of its association with estimate accuracy. Huedo-Medina
et al. [14] demonstrated that I2 suffers from low statistical
power, potentially leading to misleading results, when the
number of studies is small. Ioaniddis et al. [4] emphasized that,
like any metric, I2 has some uncertainty that can be expressed
in 95% CIs. In Cochrane meta-analyses with I2-values of ≤25%,
83% of these values had upper 95% CIs that crossed into the
range of large heterogeneity (≥50%). Even when I2 was 0%,
81% had CIs exceeding 50%. However, these intervals are still
rarely provided.
As meta-analyses have become so important in evi-
dence-based medicine, their results should be reliable and
accurate. Our ﬁndings demonstrate that heterogeneity impor-
tantly inﬂuences both aspects. As yet, there are no reliable
methods with which to quantify the amount of clinical and
methodological heterogeneity, and careful selection of appro-
priate studies is the only tool for deriving correct inferences
from meta-analyses. Unfortunately, this selection will always
be, at least to some extent, subjective. Our ﬁndings demon-
strate that determination of I2 is of little value at the extremes
of heterogeneity, and it would be helpful to derive criteria for
categorizing meta-analyses into either low or high levels of
clinical and methodological heterogeneity. The consequence
would be that meta-analyses with high levels of clinical and
methodological heterogeneity should not provide a pooled
estimate (as the level of accuracy will always be low, regardless
of I2) and that meta-analyses with low levels of heterogeneity
should not provide an estimate of I2. In real life, however, the
levels of heterogeneity of most meta-analyses will be unknown.
In such scenarios, I2 determination may help to identify
estimates with low predictive values (high I2), for which we
recommend that pooled estimates should not be provided.
With low I2-values and unknown levels of clinical and
methodological heterogeneity, predictive values of pooled
estimates may range extensively, and ﬁndings should be
interpreted with caution. Objective methods to quantify the
levels of clinical and methodological heterogeneity are urgently
needed to allow reliable determination of the accuracy of
meta-analyses. Until that time, we propose that investigators
describe the pretest likelihood of clinical and methodological
heterogeneity and carefully discuss the potential effects on
study results.
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